Analysts Anticipate Ekso Bionics Holdings Inc (NASDAQ:EKSO) Will Post Earnings of -$0.60 Per Share

Equities analysts predict that Ekso Bionics Holdings Inc (NASDAQ:EKSO) will announce earnings per share of ($0.60) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ekso Bionics’ earnings. Ekso Bionics also posted earnings per share of ($0.60) in the same quarter last year. The business is expected to announce its next earnings results on Thursday, August 6th.

According to Zacks, analysts expect that Ekso Bionics will report full year earnings of ($1.94) per share for the current fiscal year. For the next financial year, analysts anticipate that the company will post earnings of ($1.04) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Ekso Bionics.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Thursday, April 30th. The company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.17. The firm had revenue of $1.47 million for the quarter. Ekso Bionics had a negative net margin of 68.97% and a negative return on equity of 210.43%.

A number of research firms have weighed in on EKSO. Cantor Fitzgerald boosted their target price on shares of Ekso Bionics from $1.00 to $8.00 and gave the company an “overweight” rating in a research note on Wednesday, March 25th. Aegis dropped their price target on shares of Ekso Bionics from $15.00 to $13.00 and set a “buy” rating on the stock in a research note on Thursday, May 21st. ValuEngine raised shares of Ekso Bionics from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Finally, Zacks Investment Research raised shares of Ekso Bionics from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a report on Wednesday, April 1st. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $6.36.

EKSO opened at $3.95 on Tuesday. The company has a quick ratio of 1.53, a current ratio of 1.86 and a debt-to-equity ratio of 0.11. The stock has a market cap of $30.27 million, a price-to-earnings ratio of -2.41 and a beta of 2.02. Ekso Bionics has a twelve month low of $2.25 and a twelve month high of $20.85. The company’s 50-day moving average price is $3.69 and its two-hundred day moving average price is $1.51.

A hedge fund recently raised its stake in Ekso Bionics stock. Virtu Financial LLC boosted its holdings in shares of Ekso Bionics Holdings Inc (NASDAQ:EKSO) by 534.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 131,749 shares of the company’s stock after buying an additional 110,997 shares during the quarter. Virtu Financial LLC owned approximately 0.15% of Ekso Bionics worth $52,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 23.46% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.

Read More: Preferred Stock

Get a free copy of the Zacks research report on Ekso Bionics (EKSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ekso Bionics (NASDAQ:EKSO)

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.